Indaptus Therapeutics, Inc.
INDP
$2.42
$0.3919.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -68.58% | 369.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -73.52% | 207.94% | |||
| Operating Income | 73.52% | -207.94% | |||
| Income Before Tax | 68.68% | -172.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 68.68% | -172.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 68.68% | -172.68% | |||
| EBIT | 73.52% | -207.94% | |||
| EBITDA | -- | -207.95% | |||
| EPS Basic | 94.86% | -51.29% | |||
| Normalized Basic EPS | 94.86% | -51.29% | |||
| EPS Diluted | 94.86% | -51.29% | |||
| Normalized Diluted EPS | 94.86% | -51.29% | |||
| Average Basic Shares Outstanding | 509.72% | 80.24% | |||
| Average Diluted Shares Outstanding | 509.72% | 80.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||